Silence Therapeutics
在场
Silence Therapeutics 是一家在股票代码 SLN (GB) 下上市的公司。
高管
查看带有其 16 名主要高管的组织结构图
Silence Therapeutics 搜索最多的简介
- Craig Tooman, President and Chief Executive Officer
- Ian Ross, Non-Executive Chairman of the Board
- Michael Davidson, Non-Executive Director
高管在Silence Therapeutics变化
- Gianine Esposito已作为Chief Human Resources Officer加入公司 (新闻发布的2024八月18号).
- Alistair Gray, Non-Executive Director, 将于 20245月1 退休 (新闻发布的2024四月30号).
创建提醒
跟踪 Silence Therapeutics 的高管变动
药店
Silence Therapeutics 拥有 1,842 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
- Grace Therapeutics将在Oct 25, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
药店 行业的其他推荐联系人
消息
Silence Therapeutics 的最新新闻稿
- Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
- Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
- Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
- Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
- Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
- Silence Therapeutics to Present at Jefferies Global Healthcare Conference
- Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
- Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
- View more press releases Close
通过电子邮件
